Panel Meeting Durolane™ August 19th 2009

Panel Meeting Durolane™ August 19th 2009

Q-Med's Premarket Approval (PMA) application for Durolane™ in the US will be
discussed on August 19th 2009, at a public meeting of the FDA's Orthopaedic and
Rehabilitation Devices Advisory Committee. The panel is expected to consider the
clinical trial results Q-Med submitted to support the approval and labeling of
Durolane, a single dose product indicated for the treatment of pain caused by
osteoarthritis of the knee.

Queries should be addressed to:
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111

Per Langö, Senior Director Corporate Development
Tel: +46 (0)73-387 15 21

Cindy Wong, Chief Medical officer and Head of Medical Affairs
Tel: +46 (0)73-387 14 50

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
about 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. 
Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic. 

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.